Pfizer, SFJ Pharma To Conduct Phase III Asian Trials Of Carcinoma Drug
This article was originally published in PharmAsia News
U.S.-based SFJ Pharma is to conduct final-phase trials in Asia of Pfizer’s axitinib for renal cell carcinoma.
You may also be interested in...
Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.
A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall.
Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.